FDA Central Review Likely For Novel Surrogate Endpoints
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER’s Woodcock says accelerated approval requirements in 21st Century Cures legislation could create a process akin to how FDA handles breakthrough designations.